Post by
Melray on Apr 01, 2021 7:04pm
Lost opportunity!
We have all been waiting for the launch of Aristotle. Some of us for many years and this was to be the moment! the launch! stagezero's raison d'etre coming alive! To say, poorly executed is an understatement. To say a blip or bump in the road is naive! This was a wholly unnecessary catastrophe that was/is embarrassing and has damaged our credibility as a leading edge biomedical company. My immediate concern following the dog and pony show and late financial disclosure is we have now been set back in our momentum. We haven't just slowed down, we are now (suprise!) plotting a new course. Ok?maybe? But why? Were we unable to get the partnerships we hoped for? Who knows? What I do believe, is this acquisition is expensive and will require capital raised from covid to develop and time to build out. The advantage our small canadian company had was "FIRST TO MARKET" giving us street creed over the Godzillas working on Grail. I'm afraid that past advantage is limited by our display this week. I have lost all confidence in JHT and urge the Board to consider alternative leadership.
Comment by
RelevantStock on Apr 01, 2021 7:13pm
I had the exact same thoughts this morning, my thinking has evolved a little bit since. I'd like to see right now a patient bring tested with Aristotle, see the results and proof of reliability and specificity. I don't understand why we don't have partners rushing in the door.
Comment by
Jonnyboy85 on Apr 01, 2021 7:17pm
“Revenue from 2020 and 2021 supports the Company’s efforts for commercialization and marketing of AVRT and Aristotle” I think that answers your questions.
Comment by
Positivelive1 on Apr 01, 2021 7:21pm
No Partners= own your clinic with limited exposure and major overhead costs! Sorry but $2.9 million for a quarter is insignificant especially when covid will end! Sure, you might have revenue for a few quarters -